Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

cently filed Quarterly Report on Form 10-Q. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

Condensed Statements of Operations

(Unaudited)

(in thousands)

Three Months Nine Months

Ended Ended

September 30, September 30,

2008 2007 2008 2007

Operating expenses

Research and development $ 1,639 $ 1,094 $ 3,621 $ 3,075

General and administrative 1,024 609 2,243 2,709

------------------- -------------------

Total operating expenses 2,663 1,703 5,864 5,784

------------------- -------------------

Other income (expense) 297 (27) 88 44

------------------- -------------------

Loss for the period before taxes (2,366) (1,730) (5,776) (5,740)

Income tax expense (recovery) (2,515) 200 (2,100) 573

------------------- -------------------

Operating income (loss) before

extraordinary gain 149 (1,930) (3,676) (6,313)

Extraordinary gain 4,428 - 4,428 -

-------------------
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 On ... Cellular Medicine Showcase in Chicago, leading applied stem ... Surgeon, Dr. Wade McKenna presented talks on New ... Orthopedic Surgical Applications For Stem Cells. , Dr. ... membrane and the properties of AlphaGEMS that include: ...
(Date:10/30/2014)... Spartan Bioscience announced today that Health ... . It detects CYP2C19 genetic mutations in less than ... Spartan RX CYP2C19 System is the first near-patient DNA ... Canada. Due to the system’s ease of use, Health ... healthcare professionals such as doctors, nurses, pharmacists, and laboratory ...
(Date:10/30/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the leader ... company overview at the Nomura Biotechnology Conference on Thursday, November ... MA. A live webcast of the ... of the Company,s website, www.isispharm.com .  A replay will ... will be archived for a limited time. About ...
(Date:10/30/2014)... 29, 2014) – The severe flooding that devastated a ... less destructive if the bridges, roads and other infrastructure ... study from the University of Colorado Denver. , "People ... said Jimmy Kim, PhD, associate professor of structural engineering ... Science and lead author the study. "There is an ...
Breaking Biology Technology:Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2
... SAN DIEGO, March 12 Sangart, Inc., a privately ... commercialization of oxygen therapeutics, today announced the receipt of ... This investment results from the exercise of warrants issued ... round initiated in 2007. The most recent investment ...
... 12 The United States, long the beneficiary of ... workers from leaving to pursue expanding opportunities in their ... 2009 Issues in Science and Technology .In ... Duke University and Harvard Law School, writes that ...
... March 12 Boston Scientific Corporation (NYSE: ... raised the Company,s rating outlook to stable from negative. ... bond rating to Ba1 from Ba2 and its liquidity ... credit rating at Ba1. Moody,s said the revised ...
Cached Biology Technology:Sangart, Inc. Completes Series F Funding Round 2U.S. Risks Losing Highly Skilled Immigrants 2U.S. Risks Losing Highly Skilled Immigrants 3Moody's Raises Boston Scientific's Rating Outlook to Stable 2Moody's Raises Boston Scientific's Rating Outlook to Stable 3
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... Singapore (NUS) have discovered a new reproductive mode in ... eggs in live bamboo with narrow openings - which ... ( Raorchestes chalazodes ). This critically endangered frog is ... this novel reproductive strategy. The findings were published in ... the Linnean Society , in October 2014. , ...
(Date:10/27/2014)... researchers have delivered a scientific one-two punch with a ... self-assemble via their sticky ends. , Collagen is the ... bone and the fibrous tissues that support cells and ... better synthetic collagen for tissue engineering and cosmetic and ... has been studying synthetic collagen for a decade, teasing ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NUS researchers discover for the first time that a rare bush frog breeds in bamboo 2NUS researchers discover for the first time that a rare bush frog breeds in bamboo 3'Sticky' ends start synthetic collagen growth 2'Sticky' ends start synthetic collagen growth 3
... allowing us to spot prey, vision keeps many animals, including ... and why is it easier for us to spot movement ... notice other things? The complexity of the neural network that ... new technology and support from the National Science Foundation, Claire ...
... One of the many advantages of maintaining a normal ... a healthy heart. Fat tissue is increasingly seen as more ... secretory organ that normally produces high levels of a cardioprotective ... people has long been a mystery, and now a team ...
... developing a cost-effective electronic monitoring system that will enable ... by allowing users to track water-quality data from these ... National Science Foundation (NSF) grant. "Our goal is ... conditions in the Chesapeake Bay, the sounds of North ...
Cached Biology News:The zebrafish's neural circuit prevents it from biting off more than it can chew 2Study finds fat hormone's long-sought link to heart protection 2Researchers developing real-time electronic monitoring for coastal waters 2
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
Biology Products: